Compound: 3106-85-2
SMILES: O=C(O)[C@@H](NC(=O)[C@@H](NC(=O)C)CC(=O)O)CCC(=O)O
InChIKey: OPVPGKGADVGKTG-BQBZGAKWSA-N
Synonyms: 3106-85-2, Isospaglumic acid, N-Acetylaspartylglutamic acid, Acido isospaglumico, Acide isospaglumique, NAAGA, Acidum isospaglumicum, 1W8M12WXYL, N-(N-Acetyl-L-alpha-aspartyl)-L-glutamic acid, (2S)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]pentanedioic acid, N-Acetyl-1-aspartylglutamic acid, (2S)-2-(((2R)-2-acetamido-3-carboxy-propanoyl)amino)pentanedioic acid, (2S)-2-(((2S)-2-acetamido-3-carboxypropanoyl)amino)pentanedioic acid, NAAGA magnesium salt, N-acetyl-1-Asp-Glu, RefChem:792338, N-acetyl-aspartyl-glutamic acid, Zy15109, N-acetyl-L-alpha-aspartylglutamic acid, ZY15106, NAAG, N-Acetyl-Asp-Glu, N-acetylaspartylglutamate, Ac-Asp-Glu-OH, (S)-2-((S)-2-Acetamido-3-carboxypropanamido)pentanedioic acid, Isospaglumic acid [INN], L-Glutamic acid, N-acetyl-L-alpha-aspartyl-, N-Acetyl-L-aspartyl-L-glutamic acid, N-acetylaspartylglutamate (NAAG), MFCD00076652, L-Glutamic acid, N-acetyl-L-a-aspartyl-, N-acetyl-L-alpha-aspartyl-L-glutamic acid, Acide isospaglumique [French], Acido isospaglumico [Spanish], Acidum isospaglumicum [Latin], C11H16N2O8, SR-01000597665, UNII-1W8M12WXYL, spaglumic-acid, a-Spaglumic acid, alpha-Spaglumic acid, Spectrum_000399, Tocris-0391, N-acetyl-L-Asp-L-Glu, Prestwick0_001091, Prestwick1_001091, Prestwick2_001091, Spectrum2_001571, Spectrum3_000759, Spectrum4_000873, Spectrum5_001840, N-Ac-D-E, [3H]NAAG, BSPBio_002378, BSPBio_003230, KBioGR_001565, KBioSS_000879, 2-[(2-acetamido-3-carboxy-1-oxopropyl)amino]pentanedioic acid, DivK1c_000662, SCHEMBL288514, SPECTRUM1503630, SPBio_001502, SPBio_003051, GTPL1405, orb1679001, Acetyl-a-L-aspartylglutamic acid, CHEMBL1329032, DTXSID3091535, n-acetyl-a-aspartylglutamic acid, BDBM17658, CHEBI:73688, HMS502B04, KBio1_000662, KBio2_000879, KBio2_003447, KBio2_006015, KBio3_001598, ISOSPAGLUMIC ACID [MART.], NINDS_000662, HMS1571K04, HMS3411I03, HMS3675I03, N-(N-Acetylaspartyl)glutamic acid, Pharmakon1600-01503630, ISOSPAGLUMIC ACID [WHO-DD], (2S)-2-[(2S)-3-carboxy-2-acetamidopropanamido]pentanedioic acid, Acetyl-alpha-L-aspartylglutamic acid, CCG-38888, NSC758468, (2S)-2-[[(2S)-2-acetamido-4-hydroxy-4-oxobutanoyl]amino]pentanedioic acid, AKOS024457865, EBC-616047, FA05316, N-Acetyl-a-L-aspartyl-L-glutamic acid, SDCCGMLS-0066696.P001, IDI1_000662, NCGC00016651-01, NCGC00016651-02, NCGC00024569-01, NCGC00024569-02, AS-76948, BP-41200, N-Acetyl-alpha-L-aspartyl-L-glutamic acid, SBI-0052840.P002, HY-100921, L-Glutamic acid, N-acetyl-L-|A-aspartyl-, CS-0020591, NS00007578, C15544, AB00053333_02, Q2394106, SR-01000597665-1, SR-01000597665-2, BRD-K68405354-001-06-4, BRD-K68405354-001-07-2, N-(N-ACETYL-L-.ALPHA.-ASPARTYL)-L-GLUTAMIC ACID, (2S)-2-[(3S)-3-acetamido-3-formamidopropanoic acid]pentanedioic acid, (2S)-2-[[(2S)-2-acetamido-3-carboxy-propanoyl]amino]pentanedioic acid
Theoretical properties:
molecular_formula: C11H16N2O8
molecular_weight: 304.25 g/mol
exact_mass: 304.09066547 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 5
hydrogen_bond_acceptor_count: 8
rotatable_bond_count: 9
heavy_atom_count: 21
topological_polar_surface_area: 170 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Ac-Asp-Glu is a dipeptide composed of N-acetyl-L-aspartic acid and L-glutamic acid joined by a peptide linkage. It has a role as a human metabolite. It is functionally related to a L-glutamic acid and a N-acetyl-L-aspartic acid. It is a conjugate acid of an Ac-Asp-Glu(3-).
chebi: A dipeptide composed of <em>N</em>-acetyl-<small>L</small>-aspartic acid and <small>L</small>-glutamic acid joined by a peptide linkage.
chembl: ISOSPAGLUMIC ACID is a small molecule listed in the ChEMBL database and has reached clinical trial phase 2.0.
wikipedia: N-Acetylaspartylglutamic acid (N-acetylaspartylglutamate or NAAG) is a peptide neurotransmitter and the third-most-prevalent neurotransmitter in the mammalian nervous system. NAAG consists of  N-acetylaspartic acid (NAA) and glutamic acid coupled via a peptide bond.
NAAG was discovered as a nervous system-specific peptide in 1965 by Curatolo and colleagues but initially disregarded as a neurotransmitter and not extensively studied. However it meets the criteria for a neurotransmitter, including being concentrated in neurons, packed in synaptic vesicles, released in a calcium-dependent manner, and hydrolyzed in the synaptic space by enzymatic activity.
NAAG activates a specific receptor, the metabotropic glutamate receptor type 3. It is  synthesized enzymatically from its two precursors and catabolized by NAAG peptidases in the synapse. The inhibition of the latter enzymes has potentially important therapeutic effects in animal models of several neurologic conditions and disorders.
Under the INN spaglumic acid, NAAG is used as an antiallergic medication in eye drops and nasal preparations.